Diagnosis and management of AML in pediatric patients: consensus recommendations from an international expert panel
C. Michel Zwaan, Sarah K. Tasian, Richard Aplenc, Lisa Eidenschink Brodersen, Barbara Buldini, Barbara De Moerloose, Michael Dworzak, Linda Fogelstrand, Brenda Gibson, Bianca F. Goemans, Henrik Hasle, Betsy Hirsch, Gertjan J.L. Kaspers, Jan‐Henning Klusmann, Matthew A. Kutny, Thomas Lehrnbecher, Franco Locatelli, Soheil Meshinchi, Arnaud Petit, Martina Pigazzi, Anne Tierens, E. Anders Kolb, Dirk Reinhardt, Daisuke Tomizawa, Todd M. Cooper
Abstract
ABSTRACT: The European LeukemiaNet has periodically issued guidelines for the diagnosis and management of acute myeloid leukemia (AML) in adults. These consensus recommendations, most recently updated in 2022, incorporate recent advances in genomic testing, disease detection methods, target identification, and response assessment. Although similarities exist between AML in children and adults, pediatric AML is frequently characterized by unique cytogenetic and molecular features, which require distinct genetic and immunophenotypic diagnostics, therapeutic approaches, response assessment criteria, and supportive care strategies. To address these specific needs, an international panel of pediatric hematologist-oncologists, biologists, geneticists, and laboratory medicine scientists convened to develop recommendations for the diagnosis and management of AML in children, adolescents, and young adults (hereafter termed pediatric AML) that are discussed in this special report.